


Gambia

Region: West Africa

Key information on co-financing

- Gross National Income per capita (2017): **\$ 450**
- Co-financing status (2019): **Initial self-financing**
- Country is projected to stay in initial self financing phase for next 5 years.




Immunisation financing

	2013	2014	2015	2016	2017
Vaccines used in routine immunisation					
- Government expenditure	\$ 333,727	\$ 600,300	\$ 771,429	\$ 882,000	\$ 884,500
- Total expenditure	\$ 1,720,315	\$ 1,775,629	\$ 1,896,543	\$ 2,245,403	\$ 2,250,403
- Government as % of total	19%	34%	41%	39%	39%
Routine immunisation					
- Government expenditure	\$ 762,500	\$ 820,000	\$ 853,200	\$ 883,400	\$ 886,600
- Total expenditure	\$ 2,299,069	\$ 2,354,233	\$ 2,551,000	\$ 3,128,803	\$ 3,134,800
- Government as % of total	33%	35%	33%	28%	28%

Source: WHO-UNICEF Joint Reporting Form 2017

Domestic General government expenditure on health as a share of gross domestic product: **0.01%**

Expenditure on routine immunisation in 2017



Source: WHO National Health Accounts, 2015

Gavi supported vaccines

Vaccines	Type	Year(s) of Gavi support	Co-financing required
Hib mono	Routine	2002	No
Tetra DTP-Hib	Routine	2002-2009	No
HepB mono	Routine	2002-2009	No
Pentavalent	Routine	2008-present	Yes
PCV	Routine	2009-present	Yes
Measles	Routine	2012-2016	No
Meningitis A	Campaign	2013	No
Rotavirus	Routine	2013-present	Yes
HPV	Demonstration	2014-2015	No
Measles-Rubella	Campaign	2015	No
IPV	Routine	2015-present	No
Measles-Rubella	Routine	2017 - present	Yes


Co-financing payments

Year	Total amount paid by the country	Co-financed vaccines		
		Vaccine	Amount	Amount
2008	\$ 36,000	Penta	-	-
2009	\$ 90,000	Penta	-	PCV
2010	\$ 141,000	Penta	-	PCV
2011	\$ 89,000	Penta	-	PCV
2012	\$ 100,000	Penta	-	PCV
2013	\$ 141,000	Penta	Rota	PCV
2014	\$ 179,000	Penta	Rota	PCV
2015	\$ 143,000	Penta	Rota	PCV
2016	\$ 137,000	Penta	Rota	PCV
2017	\$ 111,000	Penta	Rota	PCV
2018	\$ 186,000	Penta	Rota	PCV

Co-financing obligations for 2019

	Co-financing obligations (in US\$)	Co-financing obligations (in doses)
PCV	\$ 53,500	18,000
Pentavalent	\$ 53,500	75,500
Rota	\$ 26,000	12,000
HPV	\$ 12,500	2,800
Total	\$ 145,500	

Co-financing projections for 2020 - 2024



	2020	2021	2022	2023	2024
HPV national	\$ 5,015	\$ 10,262	\$ 10,691	\$ 5,541	\$ 5,715
MenA Routine	\$ 19,127	\$ 19,509	\$ 19,809	\$ 20,105	\$ 20,397
Penta	\$ 50,380	\$ 51,384	\$ 52,175	\$ 52,954	\$ 53,722
PCV	\$ 50,380	\$ 51,384	\$ 52,175	\$ 52,954	\$ 53,722
Rota 2	\$ 31,976	\$ 32,613	\$ 33,115	\$ 33,610	\$ 34,097
Total	\$ 156,878	\$ 165,151	\$ 167,965	\$ 165,163	\$ 167,653

- Projections are based on Gavi's operational forecast version 16.
- Country is approved to introduce HPV routine in 2019.
- These projections do not guarantee renewal of support or approval of country's application.
- Final co-financing obligations will be communicated through decision letters.